Development of a Patient-reported Outcome to Measure the Health-related Quality of Life of Children, Adolescents and Young Adults With Cystinosis.

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Cystinosis is a rare congenital, inherited metabolic disorder that results in the storage of cystine in the cells of many organs of the body. In the infantile nephropathic form of the disease, only the kidney is initially affected by a loss of function, which progresses if untreated and ends in terminal renal failure by early school age. With the prolonged survival of patients due to medication and renal replacement therapy, further loss of function may occur during the course of the disease, especially in the eyes, muscles, endocrine organs and central nervous system. The quality of life of children with cystinosis is an under-researched topic. The results of the studies available so far show that the young patients and their families report a reduced quality of life and sometimes behavioral problems. To date, there are no disease specific patient reported outcome measures (PROMs) to measure the quality of life of patients with cystinosis. The aim of the study is to develop a PROM for this target group in several languages (German, English, Spanish and French) from different countries (Germany, United States, Spain, France). The PROM will focus on quality of life and will be developed for children, adolescents, and young adults including parent-report of parents with children aged 0 to 26 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 8
Maximum Age: 26
Healthy Volunteers: f
View:

• Children, adolescents, and young adults aged 8-26 years (and at least one of their parents) and further parents only of children aged 0-7

• patients have a confirmed diagnosis of cystinosis

• patients have a sufficient knowledge of the German/ English/ French or Spanish language to participate in focus interviews and complete questionnaires

• the informed consent of legal guardian and assent from the patient (if older than eight years) was given

Locations
Other Locations
Germany
University Medical Center Hamburg-Eppendorf | Center for Psychosocial Medicine | Department of Medical Psychology
RECRUITING
Hamburg
Contact Information
Primary
Julia Hannah Quitmann, PD Dr.
j.quitmann@uke.de
+49 (0) 40 7410 52789
Backup
Katharina Hohenfellner, PD Dr. med.
Katharina.Hohenfellner@ro-med.de
+49 (0861) 70532262
Time Frame
Start Date: 2022-05-01
Estimated Completion Date: 2025-05-31
Participants
Target number of participants: 300
Treatments
Children, adolescents and young adults with cystinosis and their parents
Depending on the patient's age, different HrQoL aspects are more relevant in cystinosis patients and their families. Therefore, a division based on age groups is needed to measure and interpret HrQoL measures successfully:~Age group stratification will include young patients aged 8-12, 13-17 and 18-26 for a self-reported version and children and adolescents aged 0-4, 5-7, 8-12, 13-17, 18-26 for a parent-reported version.
Related Therapeutic Areas
Sponsors
Collaborators: Leben eben! Cystinose-Selbsthilfe e.V., Cystinosis Research Network
Leads: Cystinose Stiftung

This content was sourced from clinicaltrials.gov